William Collier
Directeur/Bestuurslid bij Genevant Sciences Corp.
Vermogen: - $ op 30-04-2024
Profiel
William H.
Collier is currently a Director at Genevant Sciences Corp.
He was previously the President, Chief Executive Officer & Director at Arbutus Biopharma Corp.
from 2019 to 2023, President & Chief Executive Officer at Arbutus Biopharma, Inc., Director at International Partnership for Microbicides from 2018 to 2021, Area Director at Glaxowellcom, Director at Aids United from 2011 to 2018, and President & GM-North America Region at ViiV Healthcare Ltd.
Mr. Collier obtained an undergraduate degree from the University of Manchester Institute of Science & Technology.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 25-03-2024 | 0 ( -.--% ) | - $ | 30-04-2024 |
Actieve functies van William Collier
| Bedrijven | Functie | Begin |
|---|---|---|
Genevant Sciences Corp.
 Genevant Sciences Corp. Pharmaceuticals: MajorHealth Technology Part of Roivant Sciences Ltd., Genevant Sciences Corp. operates as a Canadian biopharmaceutical company. The company is based in Burnaby, Canada. The CEO of the company is Bo Rode Hansen. | Directeur/Bestuurslid | - |
Eerdere bekende functies van William Collier
| Bedrijven | Functie | Einde |
|---|---|---|
| ARBUTUS BIOPHARMA CORPORATION | Algemeen Directeur | 31-12-2023 |
Arbutus Biopharma, Inc.
 Arbutus Biopharma, Inc. BiotechnologyHealth Technology Arbutus Biopharma, Inc. engages in the research and development of pharmaceutical products for Hepatitis B. Its operation includes covalently closed circular DNA, Capsid Assembly, Cyclophilins, and Surface Antigen. The company was founded by Patrick T. Higgins, Michael J. Sofia, Michael J. McElhaugh, and Bryce A. Roberts in May 2012 and is headquartered in Doylestown, PA. | Algemeen Directeur | 31-12-2023 |
International Partnership for Microbicides
 International Partnership for Microbicides BiotechnologyHealth Technology The International Partnership for Microbicides develops products for the prevention of human immunodeficiency virus. The private company is based in Silver Spring, MD. | Directeur/Bestuurslid | 01-01-2021 |
| Aids United | Directeur/Bestuurslid | 01-01-2018 |
| Glaxowellcom | Corporate Officer/Principal | - |
Opleiding van William Collier
| University of Manchester Institute of Science & Technology | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| ARBUTUS BIOPHARMA CORPORATION | Health Technology |
| Bedrijven in privébezit | 6 |
|---|---|
ViiV Healthcare Ltd.
 ViiV Healthcare Ltd. Pharmaceuticals: MajorHealth Technology ViiV Healthcare Ltd. manufactures and distributes pharmaceutical products. Its medicine include Triumeq, Tivicay, Selzentry, Celesentri, Epzicom, Kivexa, Ziagen, Trizivir, Combivir, Retrovir AZT, Lexiva, Telzir, Viracept and Rescriptor. The company was founded in 2009 and is headquartered in Brentford, the United Kingdom. | Health Technology |
Genevant Sciences Corp.
Genevant Sciences Corp. Pharmaceuticals: MajorHealth Technology Part of Roivant Sciences Ltd., Genevant Sciences Corp. operates as a Canadian biopharmaceutical company. The company is based in Burnaby, Canada. The CEO of the company is Bo Rode Hansen. | Health Technology |
International Partnership for Microbicides
International Partnership for Microbicides BiotechnologyHealth Technology The International Partnership for Microbicides develops products for the prevention of human immunodeficiency virus. The private company is based in Silver Spring, MD. | Health Technology |
| Aids United | |
| Glaxowellcom | |
Arbutus Biopharma, Inc.
Arbutus Biopharma, Inc. BiotechnologyHealth Technology Arbutus Biopharma, Inc. engages in the research and development of pharmaceutical products for Hepatitis B. Its operation includes covalently closed circular DNA, Capsid Assembly, Cyclophilins, and Surface Antigen. The company was founded by Patrick T. Higgins, Michael J. Sofia, Michael J. McElhaugh, and Bryce A. Roberts in May 2012 and is headquartered in Doylestown, PA. | Health Technology |
